10-Q: Certara Reports Q1 2026 Results, Divests Medical Writing Business

Certara, Inc. reported Q1 2026 results with a net loss, while also announcing the divestiture of its global medical writing business.

Summary

• Certara, Inc. reported a net loss of $8.8 million for the first quarter of 2026, a significant decrease from a net income of $4.7 million in the same period of 2025.
• Total revenues increased slightly by 1% to $106.9 million, driven by a 7% increase in software revenues to $49.7 million, while services revenues decreased by 4% to $57.2 million.
• Operating expenses increased by $12.7 million, largely due to a $7.4 million increase in contingent consideration expense related to business acquisitions and higher general and administrative costs.
• The company completed the sale of its global medical writing and related regulatory services business to Veristat, LLC on May 8, 2026, for $85 million in cash plus an additional $15 million in escrow, with potential for up to $35 million in earn-out.
• Cash flow from operations was $11.7 million, down from $17.4 million in the prior year's quarter, and the company repurchased $40 million of its common stock during the quarter.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the reported net loss, significant increase in operating expenses, and decrease in cash flow from operations, despite a slight increase in overall revenue.

Positives

• Software revenues increased by 7% to $49.7 million, indicating strong demand and customer expansion in this segment.
• The divestiture of the medical writing business is expected to strengthen focus on core operations and AI-integrated modeling and simulation.
• The company maintains adequate liquidity, with $149.5 million in cash and cash equivalents and $100 million available under its revolving credit facility.

Negatives

• The company reported a net loss of $8.8 million for the quarter, compared to a net income of $4.7 million in the prior year.
• Services revenues decreased by 4% to $57.2 million, primarily due to lower revenue from a previously acquired business.
• General and administrative expenses increased significantly by 49% to $29.4 million, largely driven by contingent consideration expenses and other operational costs.
• Cash flow from operating activities decreased by $5.7 million to $11.7 million.

Risks

• The possibility that the previously announced divestiture of the Regulatory Medical Writing business does not close.
• Unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the divestiture transaction.
• Customer and shareholder reaction to the divestiture transaction.
• Disruption from the divestiture transaction making it more difficult to maintain business and operational relationships.
• Significant divestiture transaction costs.
• Deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development could reduce demand for products and services.
• Competition in a highly fragmented market.
• Changes or delays in government regulation relating to the biopharmaceutical industry could decrease the need for some services.
• Reduction in R&D spending by customers or delays in drug discovery and development processes may reduce demand.
• Operational disruptions, funding constraints, and policy changes at the FDA and other government agencies could adversely affect regulatory activity and the business.
• Consolidation within the biopharmaceutical industry may reduce the pool of potential customers or licenses.
• Continued revenue growth depends on the ability to successfully increase the customer base, expand relationships, and enter new markets.
• Dependence on key personnel and the risk of not retaining or recruiting qualified personnel.
• Potential adverse effects if independent contractors are characterized as employees.
• Delays or defects in the release of new or enhanced software or biosimulation tools may result in increased costs, delayed market acceptance, diminished demand, delayed or lost revenue, and liability.
• Issues relating to the implementation, use, and development of AI and machine learning may result in reputational harm, regulatory action, or legal liability.
• Failure to renew software licenses or purchase additional solutions by existing customers will negatively impact business and operating results.
• Government customers and grants subject the company to risks including early termination, audits, investigations, sanctions, or penalties.
• Regular evaluation of potential acquisitions and strategic transactions could divert management's attention, result in dilution, and disrupt operations.
• The estimated addressable market is subject to inherent challenges and uncertainties.
• Adverse global economic conditions could negatively affect business, results of operations, financial condition, and liquidity.
• Operation in a global business subjects the company to economic, political, and other risks.
• Failure to comply with trade compliance and economic sanctions laws and regulations could materially adversely affect reputation and results of operations.
• Current and future litigation could be costly and time-consuming to defend.
• Insurance coverage may not be sufficient to avoid material impact from claims or liabilities.
• Failure to perform services in accordance with contractual requirements, regulatory standards, and ethical considerations could lead to significant costs or penalties and reputational harm.
• Loss of one or more major customers could materially and adversely affect the business, results of operations, and/or financial condition.
• Need for additional funding if unable to raise capital or generate sufficient cash flows.
• Bookings might not accurately predict future revenue.
• Subject to FCPA, U.K. Bribery Act, and similar anti-corruption laws.
• Risks arising from catastrophic events, including natural disasters, extreme weather, war, terrorism, epidemics, pandemics, and public health crises.
• Reliance on third-party cloud infrastructure providers; disruptions could adversely affect business.
• Breaches in cybersecurity measures or unauthorized access to data could lead to reduced use of solutions and significant liabilities.
• Subject to numerous privacy and data security laws; non-compliance could cause significant harm.
• Failure to reliably meet data storage and management or other IT requirements could harm customer satisfaction and reputation.
• Use of third-party open-source software; failure to comply with licenses could adversely affect business.
• Inability to adequately enforce or defend intellectual property rights.
• Third-party legal proceedings alleging intellectual property infringement could have a material adverse effect.
• Indebtedness could materially adversely affect financial condition and ability to operate.
• Impairment of goodwill and other tangible assets may adversely impact future results of operations.

Future Outlook

The company expects to recognize a loss on the divestiture of its medical writing business ranging from approximately $28.9 million to $53.7 million. Net proceeds from the transaction are expected to be used for general corporate purposes, including funding ongoing operations. The company believes its existing sources of liquidity will be sufficient to meet its working capital, capital expenditures, and contractual obligations for the foreseeable future.

Management Comments

• We believe that the growth and future success of our business depend on many factors. While each of these factors presents significant opportunities for our business, they also pose important challenges that we must successfully address to sustain our growth and improve the results of our operations.
• Our goal is to enable the life science industry to use data, modeling, and analytics to make better decisions during drug research, development and commercialization to increase productivity rates and vastly reduce development costs.
• We expect to recognize a loss on the transaction ranging from approximately $28,891 to $53,658. The actual loss recognized may differ from this estimate due to final working capital adjustments, the determination of fair value measurements, and the settlement of the earn-out.
• We expect the transaction to strengthen our focus on core operations and further our commitment to accelerating AI-integrated modeling and simulation across the entire drug development lifecycle.

Industry Context

StockSavvy.ai notes that Certara's Q1 2026 results reflect ongoing trends in the biopharmaceutical services sector, with a continued emphasis on software and technology-driven solutions for drug development. The divestiture of the medical writing business aligns with a strategic focus on core biosimulation and AI-integrated capabilities, a trend observed as companies streamline operations to enhance efficiency and specialized expertise.

Comparison to Industry Standards

• Certara's reported net loss of $8.8 million for Q1 2026 contrasts with the industry's general profitability, though many companies in the life sciences services sector experience fluctuations based on project pipelines and R&D investments.
• The company's software revenue growth of 7% is a positive indicator, aligning with the broader industry trend of increasing adoption of digital tools and AI in drug discovery and development.
• The services revenue decline of 4% may indicate a shift in customer preference towards software solutions or a temporary slowdown in project-based work, a dynamic seen across some competitors facing project delays or budget reallocations.
• Certara's stated goal of reducing drug development costs, with an industry average of $6.2 billion per FDA-approved drug, positions it within a critical area of focus for pharmaceutical companies seeking efficiency gains.

Legal Proceedings

• The company does not have any pending or threatened litigation which, individually or in the aggregate, would have a material adverse effect on its condensed consolidated financial statements as of March 31, 2026.

Stakeholder Impact

• Shareholders may be impacted by the net loss reported for the quarter and the strategic divestiture, which could affect future profitability and stock performance.
• Employees in the divested medical writing business will transition to Veristat, LLC.
• Customers of the medical writing business will now be served by Veristat, LLC, with Certara providing transition services.
• Suppliers and creditors are not directly impacted by the reported financial results or the divestiture, but ongoing business operations and liquidity remain key considerations.

Next Steps

• Utilize net proceeds from the medical writing business divestiture for general corporate purposes, including funding ongoing operations.
• Continue to focus on core operations and AI-integrated modeling and simulation across the drug development lifecycle.
• Provide transition services to Veristat, LLC for a defined period following the divestiture.
• Continue to invest in scientific talent, sales and marketing, and research and development to support growth.

Key Dates

Recommendation

While the company reported a net loss and increased expenses, the strategic divestiture of a non-core asset and continued growth in software revenue suggest a potential for future improvement. The company's liquidity remains strong, and its focus on AI-integrated biosimulation is aligned with industry trends. However, the current financial performance warrants a cautious 'hold' until a clearer path to sustained profitability is demonstrated.

Keywords

Certara, 10-Q, SEC Filing, Biosimulation, Drug Development, Model-Informed Drug Development, Software, Services, Financial Results, Q1 2026, Divestiture, Medical Writing, Regulatory Services, Veristat